Trial Profile
A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Ramipril; Valsartan
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARADISE-MI
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 13 Nov 2023 Results assessing the incidence, risk factors and subsequent mortality after high-risk acute myocardial infarction and comparing the effects of sacubitril/valsartan with the ACE inhibitor ramipril across heart failure (HF) risk categories, presented at the American Heart Association Scientific Sessions 2023.
- 13 Nov 2023 Results of Subgroup Analysis exploring the safety and tolerability of sacubitril/valsartan versus ramipril when initiated in AMI in the IP, DD or OP care setting, presented at the American Heart Association Scientific Sessions 2023
- 13 Nov 2023 Results assessing Prognostic Importance of Serial NT-proBNP Measurements Following High-Risk Mi presented at the American Heart Association Scientific Sessions 2023